News & Events
Press Releases
-
1Regor Initiates Phase 2 Study of Oral Once-daily GLP-1 Agonist RGT-075 for the Treatment of Obesity
Cambridge, MA, March 8, 2024 -- Regor Therapeutics Group ("Regor"), a clinical-stage global biopharmaceutical company powered by a cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that its Phase 2 trial of the highly selective oral GLP-1 agonist RGT-075 is initiated in adults with obesity or overweight with weight-related comorbidities and has First Patient First Visit (FPFV) on Mar 08, 2024. The topline results for this Phase 2 trial are expected to be announced in the second half of 2024. “The initiation of the Phase 2 trial marks an important milestone in the development of RGT-075 as we believe it could represent a convenient and potentially meaningful alternative to the currently available weight loss treatments,” said Michael Grimm, M.D., Ph.D., Head of Metabolic Diseases at Regor. “RGT-075 is designed to be administered orally once daily as a monotherapy or as part of a potential oral combination treatment for obesity. Phase 1 clinical data showed promising exploratory body weight trends despite short treatment duration,” added Dr. Grimm.
About the RGT-075 Development Program
The Phase 2 multicenter, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily oral RGT-075 compared with placebo in adult patients with obesity or overweight with weight-related comorbidities. Approximately 60 adult participants with a BMI ≥ 27 kg/m2 and ≤ 45 kg/m2 will be enrolled and randomized to RGT-075 or placebo. The treatment will last 12 weeks; all participants on RGT001-075 will be given RGT-075 once daily (QD) titrated up over 6 weeks, then being maintained with the target dose for 6 weeks. Topline data from the Phase 2 study are expected to be announced in the second half of 2024.
About RGT-075
RGT-075 is an oral-available, once-daily, small molecule GLP-1R full agonist discovered and developed by Regor for the treatment of metabolic diseases, such as type-2 diabetes mellitus and overweight/obesity. Regor completed its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) studies. RGT-075 was safe and clinically well-tolerated in clinical trials completed to date.
About Regor Therapeutics Group
Regor Therapeutics is a global biotech company founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARDTM(Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor’s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents. Regor’s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with 2 leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity & beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/Her2- breast cancer patients. With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
2Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
+ RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study.
+ Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET).
+ The current data support the continued development of RGT-419B as a single agent, as well as in combination therapy with ET in HR+/HER2- ABC patients.BOSTON, December 7, 2023 -- Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced the results from Phase 1A single agent dose escalation study of RGT-419B, a next generation CDK4 inhibitor, in HR+ HER2- ABC patients who have progressed on prior CDK4/6is and ET. These results (cutoff date September 26, 2023) were presented today in poster session by Dr. Seth Wander from Massachusetts General Hospital at the San Antonio Breast Cancer Symposium (SABCS) taking place December 5-9, 2023, in San Antonio, Texas. The poster titled “First-in-human Phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients with HR+/HER2- ABC who have progressed on prior CDK4/6 inhibitors (PO3-18-06; NCT05304962)", highlighted that:
+ Across 12 patients with HR+HER2- ABC who have progressed on CDK4/6is and ET, RGT-419B administered as oral (PO) monotherapy in continuous 28-day cycles was safe and well-tolerated with no dose-limiting toxicities. No patients discontinued treatment with RGT-419B due to an adverse event.
+ The exposure of RGT-419B was dose proportional with long half-life and small peak to trough ratio at steady state.
+ RGT-419B demonstrated single agent efficacy in the heavily pretreated HR+/HER2- ABC patients who have progressed on CDK4/6i and ET. Three patients achieved partial responses and are still on treatment. 6 patients received treatment > 24 weeks.
+ The promising single agent efficacy of RGT-419B is consistent with the preclinical data from CDK4/6i resistant breast cancer models.
"RGT-419B demonstrates its potential to be the best-in-class next generation CDK4 inhibitor for HR+/HER2- breast cancer. The results presented today is encouraging because RGT-419B is not only safe and well tolerated, but also demonstrated single agent efficacy in heavily pre-treated HR+ HER2- ABC patients who progressed on the approved CDK4/6i and ET.” said Xiayang Qiu Ph.D., Chief Executive Officer of Regor Therapeutics Group. “These data show that RGT-419B has monotherapy opportunity in HR+ HER2- ABC patients resistant to the approved CDK4/6i and ET. With the favorable safety profile and promising monotherapy efficacy, RGT-419B has best-in-class potential as a single agent or in combination in HR+HER2- BC patients resistant to CDK4/6i, and in earlier lines of treatments. Clinical studies of single agent dose expansion and combination of RGT-419B with ET are underway."
The Phase 1 trial (NCT05304962) is a multicenter, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of RGT-419B given as monotherapy or in combination with ET in patients with HR+HER2- ABC who have progressed on CDK4/6i and ET.
Copies of the posters are available on Regor’s website under the Sciences section
About Regor Therapeutics Group
Regor Therapeutics is a global biotech company founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARDTM(Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor’s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents. Regor’s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with 2 leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity & beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/Her2- breast cancer patients. With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
3Regor Announces Poster Presentations of RGT-419B, A Next Generation CDK4 Inhibitor at the San Antonio Breast Cancer Symposium (SABCS)
BOSTON, Nov. 27, 2023 -- Regor Therapeutics ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced that a poster presentation featuring First-in-human Phase 1A study of RGT-419B, will be reported at the San Antonio Breast Cancer Symposium (SABCS), taking place December 5-9, 2023, in San Antonio, Texas.
Details of the SABCS 2023 poster presentations are:
Title: First-in-human Phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with HR+/HER2- ABC who progressed on prior CDK4/6 inhibitors Poster ID: PO3-18-06 Session Title: Poster Session 3 Date: Thursday December 7, 2023 Time: 12:00 p.m. to 2:00 p.m. CST A copy of the poster will be made available on Regor’s website under the Sciences & Technology section when it is presented at the symposium. Abstracts for the posters can be found on the SABCS website Full Program (sabcs.org).
About Regor Therapeutics
Regor Therapeutics is a global biotech company founded in 2018 by a team of scientists with a proven track record in drug discovery and executive leadership covering full cycle of drug discovery and development. By leveraging its industry-leading core strength in rCARDTM(Computer Accelerated Rational Discovery), Regor has completed 8 PCCs inhouse, with 5 INDs filed, validating Regor’s highly efficient ecosystem for accelerated discovery of innovative therapeutic agents. Regor’s in-house pipeline encompasses leading assets in metabolism, oncology and auto-immunity, with 2 leading assets: 1) RGT-075, an orally bioavailable small molecule GLP1R full agonist with best-in-class potential for obesity & beyond; and 2) RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/Her2- breast cancer patients. With a strong focus on excellence in pharmaceutical research and global competitiveness, Regor aspires to build a world-class innovation engine that promotes a winning culture of scientific excellence, strong teamwork driven by results and delivery with shared accountability and successes.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
4Regor announces China NMPA approval of the IND for RGT-264 phosphate tablet, a potent and selective HPK1 inhibitor
+ The phase 1 clinical study of HPK1 inhibitor RGT-264 phosphate tablet will be conducted in ChinaShanghai, Nov. 3, 2022 – Regor Therapeutics, a clinical-stage biotech company, announced today the Investigational New Drug (IND) Application for RGT-264 phosphate tablet, a small molecular selective hematopoietic progenitor kinase (HPK1) inhibitor has been approved by the National Medical Products Administration (NMPA) of China.
RGT-264 phosphate tablet is a highly potent and selective HPK1 inhibitor. HPK1 kinase activity suppresses the immune functions of a wide range of cells including T cells and dendritic cells (DCs) 1. Therefore, inhibiting HPK1 activity serves as a promising approach for cancer immunotherapy. Currently, there is no HPK1 inhibitor approved globally.
The phase 1 clinical trial is the first-in-human (FIH) study of RGT-264 phosphate tablet, aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary anti-tumor activity of RGT-264 as the monotherapy in subjects with advanced solid tumors.
About Regor Therapeutics Group
Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARDTM platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational chemistry, biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.
Reference
1. Wang X, Li JP, Chiu LL, et al. Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein. J Biol Chem. 2012;287(41):34091-34100. doi:10.1074/jbc.M112.371062
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
5Regor announces China NMPA approval of the IND for RGT-419B capsule, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
On April 20, 2022, Regor Therapeutics Group announced that the investigational new drug (IND) application of RGT-419B capsule, a CDK2/4/6 small molecule inhibitor, had been approved by the National Medical Products Administration (NMPA) of China. A Phase I clinical study will be conducted in Chinese patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced/metastatic breast cancer, including patients who are resistant to approved CDK4/6 inhibitors, to evaluate the safety, tolerability and pharmacokinetic profile of RGT-419B capsule.
RGT-419B is the first of a series of innovative oncology drugs being developed by Regor Therapeutics Group. The U.S. Food and Drug Administration (FDA) approved its early clinical development plan for patients with HR+/HER2- advanced/metastatic breast cancer and the dosing of the first patient was accomplished on April 8, 2022.
About RGT-419B
RGT-419B is a new generation of CDK inhibitor with an optimized kinase activity spectrum. Results from non-clinical studies showed that RGT-419B demonstrated full suppression of ER+ breast cancer cell proliferation with acquired resistance to CDK4/6 inhibitors. Additionally, RGT-419B's tumor cell suppression was further augmented when combined with a selective estrogen receptor down-regulator or a PI3K signaling pathway inhibitor.
The clinical development program of RGT-419B is designed to address the unmet medical needs of patients who are refractory or have relapsed after previous treatment, providing new opportunities to improve survival and quality of life for patients with advanced/metastatic breast cancer.
About Breast Cancer
According to the latest cancer data released by the World Health Organization International Agency for Research on Cancer (IARC), breast cancer is the most commonly diagnosed cancer worldwide, with an estimated 2.26 million new cases in 2020. In China, breast cancer is the most common malignancy among women, with 416,371 new cases and 117,174 deaths in 2020. HR+/HER2- breast cancer is the most common subtype, accounting for over 70% of female patients. Breast cancer poses a tremendous medical burden and has a significant negative impact on patients and their families in China and across the world.
About Regor Therapeutics Group
Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARDTM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
6Regor announces the first patient dosed in the U.S. in the Phase II clinical trial for RGT-075, a novel small molecule GLP-1R agonist
Shanghai, April. 12, 2022 --Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase II clinical trial of the Company’s novel oral small molecule GLP-1 receptor agonist RGT-075 in the U.S.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a well-characterized class of hypoglycemic agents used to treat patients with type 2 diabetes mellitus (T2DM). RGT-075 is a novel oral small molecule GLP-1 receptor agonist. The Phase II clinical trial is conducted in the form of randomized, multi-blind, multi-center placebo-controlled trial, exploring the efficacy and safety of RGT-075 in patients with type 2 diabetes mellitus who have poor glycemic control following metformin treatment. The first patient dosing of this trial has been completed in the U.S. The study was officially launched on March 30, 2022.
According to the International Diabetes Federation (IDF) Diabetes Survey 2021, there are an estimated 537 million adults with diabetes worldwide, and this number is expected to reach 643 million by 2030 and 784 million by 2045. Type 2 diabetes is the predominant type of diabetes and will continue to increase with rising rates of obesity and ageing.
About Regor Therapeutics Group
Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARDTM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
7Regor announces the first patient dosed in the U.S. in the Phase I clinical trial for RGT-419B, a CDK2/4/6 inhibitor for advanced/metastatic breast cancer
Shanghai, April. 8, 2022 --Regor Therapeutics Group, a clinical-stage biotech company focusing on immunology, oncology, and metabolic disorders, announced today that the first patient has been dosed in the Phase I clinical trial of the Company’s next generation targeted inhibitor RGT-419B for the treatment of breast cancer.
RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to combat the resistance to currently approved CDK4/6 inhibitors that are given in combination with endocrine-based therapy for treatment of pre/perimenopausal or postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. The Phase I clinical trial is in the form of non-randomized, open-label first-in-human clinical study, exploring ascending dose of RGT-419B in hormone receptor-positive HER-2 receptor-negative patients with advanced or metastatic breast cancer under monotherapy or combination endocrine therapy conditions. The study was initiated in March 2022 and the first patient dosing was completed in the U.S.
Preclinical studies indicates that RGT-419B has demonstrated full suppression of cancer cell proliferation in a CDK4/6 inhibitor-resistant ER+ breast cancer cell model. Also, data from preclinical studies suggest that the inhibitory effect of RGT-419B on cancer cells is further enhanced when combined with selective estrogen receptor degraders (SERD) or PI3K inhibitors.
About Regor Therapeutics Group
Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARDTM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
8Building a New Generation AI Engine and Jointly Accelerating World-Class Innovative Drug Discovery and Development
-- NVIDIA and Regor Therapeutics Group Enter into CollaborationShanghai, March 24, 2022: Regor Therapeutics Group and NVIDIA Corporation today entered into collaboration that makes Regor Therapeutics Group a unique biotech company in China to have in-depth access to NVIDIA Inception. Regor Therapeutics Group will work closely with NVIDIA to integrate high performance computing technology into Regor's proprietary Artificial Intelligence innovation platform - rCARDTM - to accelerate the discovery and development of innovative drugs.
The NVIDIA Inception is a program designed to nurture pioneering biotech startups. In this collaboration, NVIDIA will contribute its industry-leading GPU products and high performance computing to the rCARDTM platform, including NVIDIA Clara Discovery and the AutoDock-GPU suite. By leveraging GPU-powered parallel processing capabilities across multiple computing nodes, the rCARDTM platform will aim to accelerate the drug discovery process, reduce R&D costs, and improve success rate of drug development. This collaboration marks another milestone in Regor's mission to accelerate innovation and bring breakthrough innovative drugs to patients worldwide.
The rCARDTM platform is a proprietary and highly efficient drug discovery and development platform. With foundations of scientific expertise in structural biology, computational biology and computational chemistry, the rCARDTM platform fully integrates advanced artificial intelligence algorithms with the extensive knowledge and experiences of our seasoned drug hunters in drug research and discovery. Regor is aiming to expand the capabilities of the rCARDTM platform and build a new generation of world-class innovative drug discovery engine through this collaboration.
"We are very excited about AI in drug discovery and its potential disruptive impacts in our industry," said Dr. Wenge Zhong, Chief Technology Officer of Regor Therapeutics Group, "Since the inception, Regor has built an interdisciplinary team of scientists and embarked on establishing the rCARDTM platform to integrate artificial intelligence with our collective knowledge and experience in drug discovery. We are pleased to enter into this holistic collaboration with industry leader NVIDIA in AI and high performance computing to further expand and strengthen our rCARDTM platform capabilities. We hope that together NVIDIA and Regor can help to demonstrate the power of AI in the discovery and development of innovative drugs that will benefit patients around the world."
Renee Yao, director of global healthcare startups at NVIDIA, said: "We are excited to partner with Regor Therapeutics Group to unveil a new chapter in the integration of artificial intelligence into the biopharmaceutical industry. Through this partnership, we will enable Regor to systematically enhance its HPC and AI capabilities on top of NVIDIA's software-defined computing platform, accelerating the convergence of multidisciplinary technologies such as big data, artificial intelligence, high performance computing and innovative drug development. "
About Regor Therapeutics Group
Regor Therapeutics Group is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary rCARDTM (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating rCARDTM with structural biology, computational biology, computational chemistry and other disciplines, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules. To learn more about Regor, please visit us at www.regor.com.
IR Contact:
Investor Relations and Communications
Email: ir@regor.com
-
9Regor and Lilly Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders
INDIANAPOLIS and SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Regor Therapeutics Group have entered into a multi-year research collaboration and licensing agreement to discover, develop and commercialize novel therapies for metabolic disorders.
Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong and Taiwan, where Regor will maintain these rights and responsibilities. The agreement will allow each company the opportunity to fully leverage both parties' existing compounds and technologies globally to maximize patient treatment choice.
"Through this collaboration, we will have the opportunity to expand treatment options available to patients suffering from metabolic disorders," said Ruth Gimeno, Ph.D., vice president, diabetes research and clinical investigation at Lilly. "Regor's technology will also allow Lilly to further accelerate innovation and deliver breakthrough therapies in obesity and diabetes."
"In a little over three years, Regor has established a world-class research organization exemplified by our Computer Accelerated Rational Discovery platform. This collaboration is a recognition for Regor's core technology and research capabilities, but more importantly, it is an extraordinary opportunity to discover, develop and commercialize novel therapeutics to help the millions of patients in the world, "said Xiayang Qiu, Ph.D., founder CEO of Regor. "We are pleased to establish this strategic collaboration with Lilly, a top global leader in metabolic disorders such as diabetes and obesity."
Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor, subject to the parties entering into standard equity agreements. The company is also eligible to receive up to $1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development and commercial milestones, as well as tiered royalties from low-single to low-double digits on sales resulting from the agreement.
This transaction will be reflected in Lilly's reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly's 2021 non-GAAP earnings per share guidance as a result of this transaction.
About Regor Therapeutics Group
Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform. The company focuses mainly on three therapeutic areas, oncology, immunology, and metabolic disorders. By seamlessly integrating CARD with structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development, Regor has successfully assembled a world-class scientific team and established a highly efficient new drug innovation engine to enable the discovery and development of best- and first-in-class molecules. To learn more about Regor, please visit us at www.regor.com
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com. C-LLY
Lilly Forward-Looking Statement
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of a collaboration between Lilly and Regor Therapeutics, Lilly's research and development strategy, and potential payments to Regor in connection with the collaboration and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the collaboration, that the collaboration will yield commercially successful products or that Lilly will execute their strategy as expected. For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Refor to
Jordan Bishop; jordan.bishop@lilly.com; 317-473-5712 (Media)
Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investors)
Lauren Xuan; communications@qlregor.com; +86-21-31168236 (Regor Media)
Min Zhong; min.zhong@qlregor.com; +86-21-31168226 (Regor Investors)
-
10Regor Therapeutics Announces Completion of $90 Million Series B Financing
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.
Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical companies, Regor aims to establish world-class innovation capabilities and is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinical start in two years.
The Series B financing was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China. Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.
"We are very pleased with the strong support from leading life science investment firms in this financing round. We are now in a strong position to advance pre-clinical and clinical studies of multiple programs," said Dr. Xiayang Qiu, Founder and CEO of Regor. "We are looking forward to long-term collaborations with our investors, as we aim to improve the treatment outcomes for worldwide patients of chronic diseases, cancer and other life-threatening diseases."
"We are proud to support Regor Therapeutics' world-class team to expand its efforts across a larger number of programs and therapeutic areas to develop tomorrow's life-saving treatments," said Dr. Yi Shi, managing partner of Lilly Asia Ventures.
"With the next decade comes a historical moment for China's leap upwards. We are delighted to collaborate with veteran scientists, leading entrepreneurs and investment partners in biopharma industry. Together we are working hard for a better world by innovative and transformative medicines which make meaningful impacts to patients globally," said Mr. Andy Lin, founding partner of Loyal Valley Capital.
About Regor Therapeutics Group
Regor Therapeutics is a clinical stage company dedicated to the discovery and development of innovative and clinically differentiated medicines by leveraging the proprietary CARD (Computer Accelerated Rational Discovery) Platform, seamlessly integrating structural biology, computational chemistry, therapeutic biology, medicinal chemistry, and clinical development. Regor has assembled a world-class scientific team and demonstrated high efficiency in producing best- and first-in-class molecules.
About Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to become the trusted partner for exceptional entrepreneurs seeking smart capital and to build great companies developing breakthrough products that treat diseases and improve human health.
About Loyal Valley Capital
Loyal Valley Capital ("LVC"), founded in 2015, is a thematic, research-oriented private equity firm that has been a "partner of choice" for China's most promising companies. LVC has left a mark in leading players such as Tik Tok, Didi, Bilibili, Junshi, InnoCare, Akeso, Pop Mart, SUPCON. In 2020, LVC was honorably awarded the "Top 10 Most Influential Private Equity Firms in China", "Top 20 Healthcare Investor in China", "Top 10 Innovative Drug Investor in China", and "Top 20 Consumer Investor in China".
About Lanting Capital
LanTing Capital (LTC) is a cross-border, pharmaceutical-focused strategic private equity firm. Founded by pharmaceutical veterans and asset management experts, LTC leverages our unparalleled industry knowledge and network plus deep financial market know-how across the USA, China and Europe to unlock unique cross-border growth opportunities for our portfolio companies and investors. LanTing is currently operating in Princeton (USA), Milan (Italy), Saanen (Switzerland), and Hangzhou (China).
About TF Capital
TF Capital focuses on investment in the life sciences industry, primarily investing in early-stage companies with high potential. Through strategic investments in various key areas and right partnerships, TF Capital hopes to capture opportunities in the rapidly expanding Chinese life sciences market. Our investment team has vast experience and resources in industry to assist our portfolio companies.
About Vertex Ventures China
Vertex Ventures is a global network of venture capital funds, who is a member of Tamasek Holdings. The operator-investors manage portfolios in China, the U.S., Israel, India and Southeast Asia. Vertex Ventures China, founded in 2008, has offices in Beijing, Shanghai and Shenzhen. It is currently managing both Dollar and RMB funds, with assets under management of over ¥10 billion. Vertex Ventures China invests in high-growth innovative start-ups across mainland China, covering the fields of deep tech, new digital economy and healthcare. Some of its notable investments include 91 Wireless, Chipscreen, mobike, Horizon Robotics, Harbour Biomed, Changba, Edge Medical, Inmagene, Infinovo, etc.
